Stryker is investing $400 million in CMR Surgical and securing an option to buy it.
Why it matters: The alliance gives Stryker an entry into soft-tissue surgical robotics beyond its Mako orthopaedic platform. It also intensifies competition with Intuitive, Johnson & Johnson and Medtronic.
- Stryker will make an approximately $400 million preferred-equity investment in CMR Surgical.
- Stryker receives an exclusive option to acquire 100% of CMR's outstanding equity.
- Stryker will be CMR's exclusive U.S. sales agent for the Versius robotics portfolio.
- The transaction remains subject to regulatory approvals and customary closing conditions.
Stryker and Cambridge, England-based CMR Surgical announced the strategic alliance on October 12, 2026. The investment is valued at approximately $400 million, or £300 million, according to the companies' announcement.
The deal gives Stryker an exclusive option to acquire all of CMR's outstanding equity in the future. The companies did not disclose the option's exercise price, timing, valuation mechanics, expiration date or the ownership percentage Stryker will receive from the investment.
Stryker will sell CMR's Versius surgical-robotics portfolio exclusively in the United States. CMR will continue leading product development and commercialization outside the U.S., according to Sifted.
CMR's Versius platform is a modular soft-tissue surgical robot designed for flexible positioning across procedures, surgeon access points and sites of care. Versius Plus is authorized for sale in the U.S. for adult patients eligible for soft-tissue minimal-access cholecystectomy, according to CMR's U.S. product information.
Stryker said soft-tissue robotics is a high-growth adjacency to its existing strengths in endoscopy, visualization and enabling technologies. Its Mako system is primarily used in orthopaedic surgery. MedTech Dive, citing a J.P. Morgan analyst, reported more than 45,000 global Versius procedures as of early 2026.
"Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker's strengths," said Andy Pierce, Stryker's group president for MedSurg and Neurotechnology.
By the numbers
- $400 million - approximate preferred-equity investment by Stryker
- 100% - CMR equity covered by Stryker's exclusive acquisition option
- 45,000-plus - global procedures reported by MedTech Dive, citing a J.P. Morgan analyst, as of early 2026
Yes, but: The alliance is not an acquisition, and the option's terms remain undisclosed. Versius Plus currently has a limited U.S. indication, which could constrain near-term adoption.
What's next: The transaction must receive regulatory approvals and satisfy customary closing conditions. The companies did not announce a closing date.